Seagen

Seattle Genetics is a biotechnology company dedicated to the development and commercialization of monoclonal antibodies for cancer treatment. The company's leading product, lymphoma antibody drug, received accelerated approval in the United States in 2011 and was also approved in Canada in 2013, providing help for patients with relapsed Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.On October 9, 2020, Seattle Genetics, Inc. announced its renaming to Seagen, Inc.